| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Minaprine dihydrochloride manufacturers
|
| | Minaprine dihydrochloride Basic information |
| Product Name: | Minaprine dihydrochloride | | Synonyms: | n-(4-methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamin;n-(4-methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine;minaprin;Minaprin diHCl;N-(4-Methyl-6-phenylpyridazin-3-yl)-4-morpholineethanamine;TS-370;N-[4-METHYL-6-PHENYL-3-PYRIDAZINYL]-4-MORPHOLINEETHANAMINE DIHYDROCHLORIDE;MINAPRIN DIHYDROCHLORIDE | | CAS: | 25905-77-5 | | MF: | C17H22N4O | | MW: | 298.38 | | EINECS: | 247-329-8 | | Product Categories: | Active Pharmaceutical Ingredients;NAMENDA | | Mol File: | 25905-77-5.mol |  |
| | Minaprine dihydrochloride Chemical Properties |
| Melting point | 122° | | Boiling point | 531.2±50.0 °C(Predicted) | | density | 1.156±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 35 mg/mL (117.30 mM) | | pka | 6.80±0.10(Predicted) | | Major Application | forensics and toxicology
pharmaceutical (small molecule) | | InChI | 1S/C17H22N4O.2ClH/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21;;/h2-6,13H,7-12H2,1H3,(H,18,20);2*1H | | InChIKey | GNUCGROXDZMCJI-UHFFFAOYSA-N | | SMILES | Cl.Cl.Cc1cc(nnc1NCCN2CCOCC2)-c3ccccc3 |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 36 | | WGK Germany | 3 | | RTECS | QE3477830 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Minaprine dihydrochloride Usage And Synthesis |
| Originator | Cantor,Clin Midy,France,1979 | | Uses | muscle relaxant (skeletal) | | Uses | Minaprine is a central nervous system (CNS) drug through the use of analog synthesis and CYP2D6 enzyme kinetic analyses. | | Definition | ChEBI: Minaprine is a member of pyridazines, a secondary amine and a member of morpholines. It has a role as an antidepressant, a serotonin uptake inhibitor, a dopamine uptake inhibitor, a cholinergic drug and an antiparkinson drug. | | Manufacturing Process | (a) Preparation of the free base: A mixture comprising 0.1 mol (20.4 g) of 3-chloro-4-methyl-6-phenylpyridazine and 0.2 mol (26.2 g) of N-(2-aminoethyl)-morpholine in 100 ml of n-butanol, with a pinch of copper powder, was heatedunder reflux for 12 hours. At the end of this time, the hot solution was pouredinto 200 ml of cold water. The resulting mixture was filtered through asintered glass filter and the precipitate washed with ether. The filtrate and theether washings were placed in a separating funnel and extracted with two 150ml portions of ether. The ethereal layer was then extracted with about 250 mlof N sulfuric acid.
The acid solution was made alkaline with a 10% aqueous solution of sodiumcarbonate, and left to crystallize overnight.
The solution was filtered, yielding the colorless needles which wererecrystallized from isopropanol. The yield was 15 g (53%).
(b) Preparation of the hydrochloride: The base was dissolved in the smallestamount possible of anhydrous acetone. Double that volume of anhydrousether was added, and a stream of hydrogen chloride gas was passed throughthe solution. The hydrochloride salt obtained was recrystallized from absolutealcohol. The yield after recrystallization was 17 g (90%). | | Brand name | Cantor (Sanofi). | | Therapeutic Function | Antidepressant | | Biological Activity | Antidepressant |
| | Minaprine dihydrochloride Preparation Products And Raw materials |
|